Tilray Brands, a cannabis company with operations in numerous countries, has announced that its subsidiary, Aphria RX GmbH, has obtained a cannabis trading license in Germany.
The German cannabis market is projected to grow significantly, from C$1.79 billion in 2024 to C$6.88 billion by 2034.
Tilray is a prominent global cannabis lifestyle and consumer packaged goods organization, supporting over 20 brands and operating in various regions such as Canada, the United States, Europe, Australia, and Latin America.
Year-over-year, Tilray stock has experienced a 21.45% decrease, and since its inception in 2021, it has decreased by 86.77%.
This recent development allows Aphria RX to fully utilize its growing capacity, expand strains under its genetics program, and gain access to distribution channels in Germany.
Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International, emphasized the company’s commitment to responsible cannabis regulation, research, and accessibility to high-quality products.
Tilray’s stock is currently trading at C$2.60 per share, showing a 2.36% increase. Interested individuals can join discussions about the company on the Tilray Brands Inc. Bullboard and Stockhouse’s stock forums.
Please note that the information provided in this article is for informational purposes only and should not be considered as investment advice. For the full disclaimer, please refer to the provided link.
